WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 574224
Description: 3-hydroxy Darifenacin is a metabolite of darifenacin. It is an antagonist of M1-5 muscarinic receptors.
MedKoo Cat#: 574224
Name: 3-hydroxy Darifenacin
Chemical Formula: C28H30N2O3
Exact Mass: 442.2256
Molecular Weight: 442.56
Elemental Analysis: C, 75.99; H, 6.83; N, 6.33; O, 10.85
Synonym: 3-hydroxy Darifenacin, UK 148993
IUPAC/Chemical Name: 2-((3S)-1-(2-(3-hydroxy-2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide
InChi Key: MQEQBFMESJKUBQ-XQZUBTRRSA-N
InChi Code: InChI=1S/C28H30N2O3/c29-27(32)28(21-7-3-1-4-8-21,22-9-5-2-6-10-22)23-14-16-30(18-23)15-13-20-11-12-26-24(17-20)25(31)19-33-26/h1-12,17,23,25,31H,13-16,18-19H2,(H2,29,32)/t23-,25?/m1/s1
SMILES Code: NC(C(C1=CC=CC=C1)(C2=CC=CC=C2)[C@H]3CN(CCC4=CC=C(OCC5O)C5=C4)CC3)=O
Appearance: Solid powder
Purity: >95% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 442.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Beaumont, K.C., Cussans, N.J., Nichols, D.J., et al. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 28(1), 63-75 (1998).
2. Kerbusch, T., Wählby, U., Milligan, P.A., et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. 56(6), 639-652 (2003).
3. Mansfield, K.J., Chandran, J.J., Vaux, K.J., et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J. Pharmacol. Exp. Ther. 328(3), 893-899 (2009).